Bioextrax AB (publ) (BIOEX.ST)
SEK 3.4
(0.59%)
SEK 3.4
(0.59%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -23.31 Million | -17.6 Million | -8.47 Million | -4.17 Million | -3.17 Million | 520.5 Thousand |
| Net Income | -21.5 Million | -18.66 Million | -10.53 Million | -5.57 Million | -1.98 Million | -887.12 Thousand |
| Depreciation & Amortization | 861 Thousand | 477 Thousand | 349.52 Thousand | 172.39 Thousand | 113.22 Thousand | 32.56 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -2.66 Million | 586 Thousand | 1.7 Million | 1.22 Million | -1.29 Million | 1.37 Million |
| Other non-cash items | 4.38 Million | 368 Thousand | -1 Million | -881.31 Thousand | 1.52 Million | -1.3 Million |
| Investing Cash Flow | -1.1 Million | -6.77 Million | -975.13 Thousand | -151 Thousand | -610.84 Thousand | -115.83 Thousand |
| Investments in PPE | -1.1 Million | -6.77 Million | -975.13 Thousand | -151 Thousand | -610.84 Thousand | -115.83 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -1.1 Million | - | - | - | - | - |
| Financing Cash Flow | 10.27 Million | 42.93 Million | 16.37 Million | 5.79 Million | 2.92 Million | 990.87 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 10.27 Million | 42.93 Million | 16.37 Million | 5.79 Million | 2.92 Million | 990.87 Thousand |
| Other Financing Activities | -511 Thousand | - | - | - | - | - |
| Accounts receivables | 1.5 Million | -734 Thousand | -2.05 Million | 149.32 Thousand | -377.03 Thousand | 222.95 Thousand |
| Accounts payables | -4.17 Million | 1.32 Million | 3.76 Million | 1.07 Million | -917.68 Thousand | 1.15 Million |
| Inventory | - | - | - | - | - | - |
| Other working capital | -4.17 Million | - | - | - | - | - |
| Cash at beginning of period | 27.53 Million | 8.97 Million | 2.05 Million | 584.97 Thousand | 1.44 Million | 44.77 Thousand |
| Cash at end of period | 13.39 Million | 27.53 Million | 8.97 Million | 2.05 Million | 584.97 Thousand | 1.44 Million |
| Capital Expenditure | -1.1 Million | -6.77 Million | -975.13 Thousand | -151 Thousand | -610.84 Thousand | -115.83 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -14.13 Million | 18.55 Million | 6.92 Million | 1.46 Million | -855.34 Thousand | 1.39 Million |
| Free Cash Flow | -24.41 Million | -24.38 Million | -9.45 Million | -4.32 Million | -3.78 Million | 404.67 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -4.81 Million | -4.87 Million | -6.24 Million | -21.5 Million | -5.5 Million | -5.54 Million |
| Depreciation & Amortization | 288 Thousand | 307 Thousand | 309 Thousand | 861 Thousand | 232 Thousand | 185 Thousand |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 16 Thousand | -1.16 Million | 805 Thousand | -2.66 Million | -751 Thousand | 191 Thousand |
| Other non-cash items | 13 Thousand | 1.77 Million | -186 Thousand | 4.38 Million | 1.21 Million | 180 Thousand |
| Investing Cash Flow | - | - | - | -1.1 Million | -47 Thousand | -437 Thousand |
| Investments in PPE | - | - | - | -1.1 Million | -47 Thousand | -437 Thousand |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | 8.92 Million | - | - | 10.27 Million | 10.05 Million | - |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 10.49 Million | - | - | 10.27 Million | 10.05 Million | - |
| Other Financing Activities | -1.57 Million | - | - | - | - | - |
| Accounts receivables | -224 Thousand | 177 Thousand | 360 Thousand | 1.5 Million | 617 Thousand | 713 Thousand |
| Accounts payables | 426 Thousand | -1.33 Million | 445 Thousand | -4.17 Million | -1.36 Million | -522 Thousand |
| Inventory | - | - | - | - | - | - |
| Other working capital | 240 Thousand | - | - | - | - | - |
| Cash at beginning of period | 7.67 Million | 13.39 Million | 18.52 Million | 27.53 Million | 14.54 Million | 20.14 Million |
| Cash at end of period | 12.1 Million | 7.67 Million | 13.39 Million | 13.39 Million | 18.52 Million | 14.54 Million |
| Capital Expenditure | - | - | - | -1.1 Million | -47 Thousand | -437 Thousand |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | 4.42 Million | -5.72 Million | -5.12 Million | -14.13 Million | 3.97 Million | -5.6 Million |
| Free Cash Flow | -4.49 Million | -5.72 Million | -5.12 Million | -24.41 Million | -6.07 Million | -5.6 Million |
GXI
MKKGY
CJR-B
GEN
7965
0HOH